Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
fda
3
×
life sciences
national blog main
san diego blog main
3
×
san diego top stories
boston blog main
boston top stories
new york blog main
achaogen
adams street partners
alder biopharmaceuticals
amgen
antibiotics
beta lactamase inhibitor
biomedical advanced research and development authority (barda)
biotech ipos
boston
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
chronic migraine
david rind
deals
detroit blog main
detroit top stories
drug resistance
drugs
dyne therapeutics
eli lilly
episodic migraine
eptinezumab
erenumab
food and drug administration
fremanezumab
galcanezumab
hatteras venture partners
indiana blog main
indiana top stories
What
drug
3
×
medicines
3
×
company
therapeutics
amgen
approval
bacteria
biopharma
brings
business
candidates
class
developed
developing
disease
disorders
dyne
dyne’s
exited
fda
fighting
genetic
gets
head
infections
infectious
ipo
launches
melinta
migraine
million
muscle
muscular
new
nod
pain
preclinical
preventive
products
qpex
Language
unset
Current search:
fda
×
drug
×
" san diego blog main "
×
medicines
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines